Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #1277
Reference
Name
Review of the utility of the pain reliever co-proxamol (distalgesic; cosalgesic; dolgesic) and request for evidence on risks and benefits
Categories
Scottish Government
Organization
Medicines & Healthcare products
Keywords
NHS
SCOTLAND
PAIN RELIEF
ANALGESICS
TREATMENT
DRUG THERAPY
EFFECTIVENESS
RISKS
SAFETY
MORTALITY
Description
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently conducting a review of the risks and benefits of co-proxamol, in the light of longstanding concerns about safety and efficacy and more recent data concerning safety in overdose.
This letter seeks further available information relevant to the review.
This letter seeks further available information relevant to the review.
Contact Name
Contact Address
Created
2004-06-30 00:00:00
Download URL
Click to go back to homepage